Clinical Trials

The Seattle Times reports  on a new drug that SCCA's Andrei Shustov calls a "major breakthrough in T-cell lymphoma therapy." The drug, SGN-35, targets malignant cancer cells and stops them from dividing. The drug was developed by Seattle Genetics, which plans to apply to the FDA for conditional approval of SGN-35 in the first half of 2011. SCCA has several trials involving SGN-35. Just type "SGN-35" in the Search box above.

VTX-2337 for Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (7406)

Phase I Clinical Trial of VTX-2337, a small molecule Toll-Like Receptor 8 (TLR8) agonist in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinomas of the head and neck (SCCHN)

Ampligen w/Vaccine Therapy for Stage II-IV HER2-Positive Breast Cancer (7425)

Phase I-II Study of HER2 Vaccination with poly(I) Poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients

PF-00299804 vs. Erlotinib for Advanced Non-Small Cell Lung Cancer (UW1108)

A Randomized, Double-Blind Phase 3 Study Of PF-00299804, A Pan-Her Inhibitor, Vs. Erlotinib For The Treatment Of Advanced Non-Small Cell Lung Cancer Following Progression After, Or Intolerance To, At Least One Prior Chemotherapy

Trastuzumab-DM1 for Metastatic Breast Cancer - (MARIANNE)

A Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer

PEGPH20 for Stage IV Previously Untreated Pancreatic Cancer

A Phase 1b/2 Multicenter, International, Randomized, Double Blind, Placebo-Controlled, Study of Gemcitabine (Gemzar) Combined With PEGPH20 Compared to Gemcitabine Combined With Placebo in Patients With Stage IV Previously Untreated Pancreatic Cancer

Radiation Therapy + Cisplatin & Etoposide for Inoperable NSCLC (7506)

A Phase I dose-intensification study using radiation therapy and concurrent cisplatin and etoposide for patients with inoperable non-small cell lung cancer